Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

The team, consisting of researchers from University College London (UCL) and Queen Square Analytics, analysed 634 patients ...

The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

MINNEAPOLIS – Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, ...

New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication. The international, multi-site ...

Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive disease-modifying drugs, a new study has found. Uncertainty about the impact of these drugs during pregnancy ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...